Phase III, multicenter, randomized, double-blind, placebo-controlled study of norursodeoxycholic acid in metabolic dysfunction-associated steatotic liver disease patients
NorUDCA 1500 mg demonstrated clinically meaningful therapeutic efficacy in patients with MASLD, accompanied by consistently favorable safety profile.
Authors
- Veerendra Kumar Panuganti (ORCID: https://orcid.org/0009-0004-2623-5032)
- Chandrasekhar Varma Alluri (ORCID: https://orcid.org/0009-0009-5362-1007)
- Mamatha Reddy Dundigalla (ORCID: https://orcid.org/0000-0001-8930-7153)
- Pavan Kumar Madala
- Sanyasirao KSSVV
- Javeed Mohammad
- Althaf Shaik
Institutions
- Shilpa (India) (IN)
- Bioanalytica (Switzerland) (CH)
Publication Details
- Journal
- World Journal of Hepatology
- Published
- 2025-12-26
- DOI
- https://doi.org/10.4254/wjh.v17.i12.113658
- Citations
- 1
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.35